Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Philippe Durand

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Anti-Cancer Drugs|August 21, 2002
Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxineJean-Philippe Durand, François Goldwasser
Anti-Cancer Drugs|July 11, 2003
Protection against oxaliplatin acute neurosensory toxicity by venlafaxineJean-Philippe Durand, Catherine Brezault, François Goldwasser
Anti-Cancer Drugs|April 23, 2005
Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathyJean-Philippe Durand, Jérôme Alexandre, Loic Guillevin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 19, 2011
Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patientsJean-Philippe Durand, Olivier Mir, Romain Coriat, et al.
Anti-Cancer Drugs|February 12, 2009
Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experienceOlivier Mir, Jérôme Alexandre, Stanislas Ropert, et al.
Nutrition and Cancer|October 9, 2013
Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancerAnatole Cessot, Romain Coriat, Oliver Mir, et al.
Investigational New Drugs|August 28, 2010
Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patientsRomain Coriat, Olivier Mir, Anatole Cessot, et al.
Clinical Nutrition ESPEN|October 2, 2022
Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patientsCamille Tlemsani, Jean-Philippe Durand, Bruno Raynard, et al.
BMJ Supportive & Palliative Care|March 22, 2014
Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patientsIsabelle Colombet, Vincent Montheil, Jean-Philippe Durand, et al.
Cancer Chemotherapy and Pharmacology|February 16, 2010
Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcomaOlivier Mir, Stanislas Ropert, Antoine Babinet, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Anti-Cancer Drugs|August 21, 2002
Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxineJean-Philippe Durand, François Goldwasser
Anti-Cancer Drugs|July 11, 2003
Protection against oxaliplatin acute neurosensory toxicity by venlafaxineJean-Philippe Durand, Catherine Brezault, François Goldwasser
Anti-Cancer Drugs|April 23, 2005
Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathyJean-Philippe Durand, Jérôme Alexandre, Loic Guillevin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 19, 2011
Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patientsJean-Philippe Durand, Olivier Mir, Romain Coriat, et al.
Anti-Cancer Drugs|February 12, 2009
Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experienceOlivier Mir, Jérôme Alexandre, Stanislas Ropert, et al.
Nutrition and Cancer|October 9, 2013
Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancerAnatole Cessot, Romain Coriat, Oliver Mir, et al.
Investigational New Drugs|August 28, 2010
Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patientsRomain Coriat, Olivier Mir, Anatole Cessot, et al.
Clinical Nutrition ESPEN|October 2, 2022
Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patientsCamille Tlemsani, Jean-Philippe Durand, Bruno Raynard, et al.
BMJ Supportive & Palliative Care|March 22, 2014
Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patientsIsabelle Colombet, Vincent Montheil, Jean-Philippe Durand, et al.
Cancer Chemotherapy and Pharmacology|February 16, 2010
Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcomaOlivier Mir, Stanislas Ropert, Antoine Babinet, et al.
Pageof 4